BioNeutral’s Ygiene™ Kills Dangerous MRSA in Seconds
27 August 2009 - 10:29PM
Business Wire
BioNeutral Group, Inc. (“BioNeutral”) (OTCBB:BONU), a specialty
chemical technology based life science company, reports that its
Ygiene™ Hospital Grade Antimicrobial passed the AOAC Use Dilution
test by totally eradicating all
five million colony forming units of MRSA in less than one minute
(fifty-nine seconds) at room temperature. The required
EPA testing procedures occurred at ATS Labs.
MRSA, or Methicillin-resistant Staphylococcus aureus, is a very
serious health threatening microorganisms present in many health
care facilities and community environments. MRSA is one of the more
serious antibiotic resistant heath threatening microorganisms that
contributes to Hospital Acquired Infections (HAI’s). In the U.S.
alone, over two million people annually are afflicted with Hospital
Acquired Infections with approximately one hundred thousand people
dying. Worldwide Hospital Acquired Infections are on the rise and
will lead to hundreds of thousands needless deaths annually. MRSA
is also becoming a serious issue associated with Community Acquired
Infections such as school and campus settings. With its power to
rapidly and totally eliminate MRSA in less than one minute,
BioNeutral’s Ygiene™ Hospital Grade Antimicrobial will be a
significant part of the future solution for controlling Hospital
Acquired Infections and Community Acquired Infections.
“These independent ATS Labs test results completely validate our
internal product development efforts,” said BioNeutral Chief
Scientist for BioNeutral, Dr. Andrew Kielbania. “The level of
efficacy demonstrated in these independent tests is exceptional.
Passing this difficult EPA required test for the elimination of
MRSA is consistent with the ability of our Ygiene™ Hospital Grade
Antimicrobial to address a very serious unmet need associated with
Hospital Acquired Infections in the health care area. We believe
our Ygiene™ Hospital Grade Antimicrobial will contribute to the
saving of many lives in addition to resources at health care
facilities.”
“We often use independent labs to support our in-house work, and
are very pleased with these test results,” said Stephen Browand,
CEO at BioNeutral. “We use tests that demand exceptional
performance from our antimicrobial products. Current disinfectants
on the market are clearly not doing the job when it comes to
controlling HAIs; we believe that our antimicrobial products will
help remedy that unacceptable situation. Given these impressive
results, we have every confidence that our Ygiene Hospital Grade
Antimicrobial will have a major impact in reducing Hospital
Acquired Infections and saving lives while protecting the
environment.”
About ATS Labs
ATS Labs is a leading internationally recognized lab used by the
developers and users of antimicrobial products. They provide
comprehensive antimicrobial services and their superior client
service and scientific data have earned them a distinguished record
of acceptance with regulatory agencies in the US, Canada and the
world. For more information, visit http://www.ats-labs.com.
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in
Newark, New Jersey, BioNeutral Group, Inc., is a chemical
technology-based Life Science company that intends to commercialize
a combinational chemistry-based technology which can neutralize
harmful environmental contaminants, toxins and dangerous
micro-organisms including bacteria, viruses, mold, fungi and
spores. The formulations, including Ygiene™ and Ogiene™, which are
eco-friendly and include natural and common ingredients which are
found in baby products and in every day foods. The Company has
combined these widely-used compounds in highly specialized ways to
create products that dramatically enhance disinfecting and cleaning
results; products include BioNeutralizers and ChemoNeutralizers.
BioNeutral’s proprietary platform technology has been proven
effective in surface, water and airborne applications.
More information about the Company may be found at
www.bioneutralgroup.com
Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its
competitors. The results are published to let shareholders know how
the Company's technology compares with known formulations in the
market place. Any product claim for antimicrobial activity requires
approval from the EPA or FDA, depending upon where and how the
formulations are used. The EPA and FDA have not reviewed or
confirmed the Company's data and findings. BioNeutral's
antimicrobial formulations will be marketed under the brand name
Ygiene™ and are not yet available for sale in the United
States.